Cipla USA, Inc.: Nilotinib Capsules, 150 mg per capsule
Recall reason: Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection test.. Recalled by Cipla USA, Inc.. Distribution: U.S.A. Nationwide. Classification (Class III — minor violation). Affected lots/NDC/dates: Lot #: 5GJ0220, 5GJ0221, 5GJ0222, Exp 04/30/2027. Return the recalled medication to the pharmacy where you purchased it for a full refund of the purchase price.
📬 Get email alerts for new Product Recalls & Refunds
Free — we'll email you when new matching opportunities appear. No spam, unsubscribe anytime.
New here? Here's how Reward Opportunity works:
🔔 More Product Recalls & Refunds
Product recalls offering refunds, replacements, or repairs to consumers who purchased the item.
Browse all product recalls & refunds →Not just this one — find everything you qualify for
Our AI scans 8,000+ bounties, settlements, grants, recalls, and paid studies against your profile to rank what you can actually claim.
Get My Free Match Report